The Global Meperidine (Demerol) Market, By Form (Tablet, Injection, and Syrup), By Application (Anesthesia, Cough Treatment, and Diarrhea Treatment), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa) is estimated to be valued at US$ 493.4 Million in 2023 and is expected to exhibit a CAGR of 1.5 % during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
The initiatives by key market players to carry clinical trials can drive the growth of the global Meperidine (Demerol) market over the forecast period. For instance, a clinical trial was initiated on January 31, 2022, by University of Washington to compare pediatric dental oral sedation outcomes using midazolam and hydroxyzine with and without meperidine in children aged 3-7 years. The study was completed on February 2, 2023. The study found that patients who received oral sedation using midazolam, hydroxyzine with meperidine experienced fewer behavioral failures than those who received oral sedation using midazolam and hydroxyzine without meperidine. Such findings can increase the demand for meperidine.
Global Meperidine (Demerol) Market - Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of drugs from one place to another.
COVID-19 had a negative impact on the global meperidine (Demerol) market due to reduction in the number of surgeries being performed in hospitals. For instance, according to an article published by Jama Network on December 8, 2021, a study carried out in period of January 1, 2019 to January 30, 2021 in 49 U.S. states healthcare institutes on nearly 13 million U.S. surgical procedures showed that there was 48% decrease in the total surgical procedures volume after March 2020 due to a surge in COVID-19 cases.
Global Meperidine (Demerol) Market: Key Developments
Strategies like mergers and acquisitions can increase the reach of the products and customer base of the acquiring company, and the product can reach more regions. This is expected to boost the market growth during the forecast period.
For instance, on April 21, 2022, Hikma Pharmaceuticals PLC, a U.K.-based pharmaceutical company acquired Custopharm Inc., a U.S.-based healthcare company with an initial cash transaction of US$ 375 million on debt and cash free basis and US$ 50 million payable upon the achievement of certain commercial milestones. The combination with Custopharm enhances Hikma’s research and development capabilities. It also expands Hikma’s product portfolio to 130 commercialized injectable medicines.
Browse 27 Market Data Tables and 31 Figures spread through 150 Pages and in-depth TOC on “Global Meperidine (Demerol) Market”- Forecast to 2030, Global Meperidine (Demerol) Market, By Form (Tablet, Injection, and Syrup), By Application (Anesthesia, Cough Treatment, and Diarrhea Treatment), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
Key Takeaways of the Global Meperidine (Demerol) Market:
- The global meperidine (Demerol) market is expected to exhibit a CAGR of 1.5 % during the forecast period. Increasing research and development activities of meperidine are boosting the demand for meperidine (Demerol) and offering lucrative growth opportunities for market players in the global meperidine (Demerol) market. For instance, according to an article published by The Official Journal of Iranian Society of Regional Anesthesia and Pain Medicine on April 10, 2020, a study was performed to check the effect of meperidine on mothers and newborn for pain management after caesarean section surgery. It was conducted by Tehran University of Medical Sciences, Iran and Nursing and Midwifery Care Research Center, Iran on 1,494 patients. It was found that patients who received intrathecal meperidine experienced lower shivering and longer analgesia after surgery.
- Among application, the anesthesia segment is expected to grow in the global meperidine (Demerol) market over the forecast period. This is because increasing use of meperidine as anesthetic agent in research and development activities. For instance, according to a study published on May 12, 2021 in Acta Biomedica, meperidine reduces active phase of labor duration and has favorable analgesic effect in treating labor pain. Meperidine is not associated with maternal or neonatal complications. Hence it can be considered as an acceptable agent for use during active phase of labor. Active phase of labor is when contractions are regular and cervix has dilated to 6 centimeters. The study was conducted on 102 patients in the meperidine treated group and 92 patients in the control group.
- Among region, North America is expected to be the dominant region in the global meperidine (Demerol) market owing to the increasing research activities in this region. According to an article published by Secondary Veterinary Surgery and Anesthesiology on December 23, 2020, the effect of meperidine on blood histamine, tryptase, and immunoglobuline concentrations of animal model was determined. Six horses were enrolled in study with one treatment per day and seven day washout period. No evidence of anaphylactoid or anaphylactic type reactions occurred following intramuscular or subcutaneous meperidine administration. Hence the administration of meperidine was considered to be safe.
- The major players operating in the global meperidine (Demerol) market include Pfizer, Inc., Hikma Pharmaceuticals USA Inc., Epic Pharma, Inc., Vintage Pharmaceuticals, Inc., Sanofi, Janssen Pharmaceuticals, Boehringer Ingelheim, Sun Pharmaceutical, Egalet Corporation, and Mallinckrodt Pharmaceuticals.